Compare Stocks: PPCB, PMCB, XBIO, and CELZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$0.53 -14.4%	$0.82	$0.53 ▼ $4.72	$4.68M	2.1	106,053 shs	153,039 shs
PMCB Nuvilex	$6.68 -12.5%	$0.52	$4.69 ▼ $28.69	$4.32M	0.78	185,365 shs	126,686 shs
PPCB Propanc Biopharma	$1.92 -0.3%	$4.57	$1.63 ▼ $315.00	$1.22M	3.55	39,572 shs	9,307 shs
XBIO Xenetic Biosciences	$1.67 +0.8%	$2.42	$1.58 ▼ $4.94	$3.80M	2.36	23,888 shs	9,707 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	0.00%	-15.10%	-35.42%	-56.71%	-82.34%
PMCB Nuvilex	0.00%	+1,755.56%	+1,769.05%	+1,112.34%	+684.59%
PPCB Propanc Biopharma	0.00%	+8.19%	-43.92%	-84.30%	-99.09%
XBIO Xenetic Biosciences	0.00%	-7.77%	-16.72%	-48.96%	-36.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$0.53 -14.4%	$0.82	$0.53 ▼ $4.72	$4.68M	2.1	106,053 shs	153,039 shs
PMCB Nuvilex	$6.68 -12.5%	$0.52	$4.69 ▼ $28.69	$4.32M	0.78	185,365 shs	126,686 shs
PPCB Propanc Biopharma	$1.92 -0.3%	$4.57	$1.63 ▼ $315.00	$1.22M	3.55	39,572 shs	9,307 shs
XBIO Xenetic Biosciences	$1.67 +0.8%	$2.42	$1.58 ▼ $4.94	$3.80M	2.36	23,888 shs	9,707 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	0.00%	-15.10%	-35.42%	-56.71%	-82.34%
PMCB Nuvilex	0.00%	+1,755.56%	+1,769.05%	+1,112.34%	+684.59%
PPCB Propanc Biopharma	0.00%	+8.19%	-43.92%	-84.30%	-99.09%
XBIO Xenetic Biosciences	0.00%	-7.77%	-16.72%	-48.96%	-36.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
PMCB Nuvilex	1.00	Sell	N/A	N/A
PPCB Propanc Biopharma	1.00	Sell	N/A	N/A
XBIO Xenetic Biosciences	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PPCB, PMCB, XBIO, and CELZ Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	XBIO Xenetic Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/24/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	PPCB Propanc Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CELZ Creative Medical Technology	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/18/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELZ Creative Medical Technology	$3K	1,336.45	N/A	N/A	$0.92 per share	0.57
PMCB Nuvilex	N/A	N/A	N/A	N/A	$3.10 per share	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	$28.40 per share	N/A
XBIO Xenetic Biosciences	$2.98M	1.29	N/A	N/A	$3.23 per share	0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELZ Creative Medical Technology	-$5.99M	-$1.99	N/A	N/A	N/A	N/A	-101.97%	-96.74%	N/A
PMCB Nuvilex	-$19.42M	-$2.31	N/A	N/A	N/A	N/A	-12.99%	-8.92%	12/16/2026 (Estimated)
PPCB Propanc Biopharma	-$18.86M	-$242.50	N/A	N/A	N/A	N/A	-171.31%	-125.33%	N/A
XBIO Xenetic Biosciences	-$2.68M	-$1.16	N/A	N/A	N/A	-123.72%	-53.79%	-47.26%	N/A

Latest PPCB, PMCB, XBIO, and CELZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q1 2027	PPCB Propanc Biopharma	N/A	-$12.22	N/A	-$12.22	N/A	N/A
11/12/2026	Q3 2026	XBIO Xenetic Biosciences	N/A	-$0.72	N/A	-$0.72	N/A	$0.73 million
11/6/2026	Q3 2026	CELZ Creative Medical Technology	-$0.24	-$0.40	-$0.16	-$0.40	N/A	N/A
9/25/2026	Q4 2026	PPCB Propanc Biopharma	N/A	-$17.74	N/A	-$17.7390	N/A	N/A
9/14/2026	Q1 2027	PMCB Nuvilex	-$0.06	-$0.54	-$0.48	-$10.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELZ Creative Medical Technology	N/A	23.68	12.90
PMCB Nuvilex	N/A	40.28	40.28
PPCB Propanc Biopharma	N/A	2.55	2.55
XBIO Xenetic Biosciences	N/A	7.43	7.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELZ Creative Medical Technology	1.42%
PMCB Nuvilex	34.24%
PPCB Propanc Biopharma	N/A
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
CELZ Creative Medical Technology	1.00%
PMCB Nuvilex	10.98%
PPCB Propanc Biopharma	33.07%
XBIO Xenetic Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELZ Creative Medical Technology	4	7.59 million	7.52 million	Not Optionable
PMCB Nuvilex	2	10.76 million	9.56 million	Optionable
PPCB Propanc Biopharma	2	630,000	424,000	Not Optionable
XBIO Xenetic Biosciences	2	2.29 million	2.12 million	Not Optionable

PPCB, PMCB, XBIO, and CELZ Headlines

Recent News About These Companies

Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates

November 13 at 11:05 AM | cincinnati.comC

Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance

November 4, 2026 | finance.yahoo.com

Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis

October 16, 2026 | defenseworld.netD

Xenetic Biosciences doses first patient in DNase and CAR T-cell study

October 15, 2026 | streetinsider.com

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in ...

October 15, 2026 | finance.yahoo.com

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

October 15, 2026 | accessnewswire.comA

Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)

September 27, 2026 | defenseworld.netD

Xenetic Biosciences (NASDAQ: XBIO) to Acquire 85% Stake in Santersus AG in All-Stock Deal

September 18, 2026 | kalkinemedia.comK

Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused Pipeline

September 17, 2026 | rttnews.com

Xenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NET

September 16, 2026 | es.finance.yahoo.com

Xenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stake

September 16, 2026 | msn.com

Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript

September 16, 2026 | seekingalpha.com

Xenetic Biosciences to acquire Santersus AG in all-stock deal

September 16, 2026 | streetinsider.com

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

September 16, 2026 | accessnewswire.comA

Xenetic Biosciences Inc.

September 5, 2026 | barrons.com

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

August 7, 2026 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...

June 4, 2026 | finance.yahoo.com

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

June 4, 2026 | accessnewswire.comA

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

June 1, 2026 | accessnewswire.comA

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

May 13, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB, PMCB, XBIO, and CELZ Company Descriptions

Creative Medical Technology NASDAQ:CELZ

$0.53 -0.09 (-14.35%)

Closing price 11/13/2026 03:56 PM Eastern

Extended Trading

$0.54 +0.01 (+1.31%)

As of 11/13/2026 06:17 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Nuvilex NASDAQ:PMCB

$6.68 -0.96 (-12.54%)

Closing price 11/13/2026 03:52 PM Eastern

Extended Trading

$6.74 +0.06 (+0.82%)

As of 11/13/2026 07:30 PM Eastern

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Propanc Biopharma NASDAQ:PPCB

$1.92 -0.01 (-0.26%)

Closing price 11/13/2026 03:58 PM Eastern

Extended Trading

$1.88 -0.04 (-1.83%)

As of 11/13/2026 07:30 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Xenetic Biosciences NASDAQ:XBIO

$1.67 +0.01 (+0.84%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$1.72 +0.05 (+3.05%)

As of 11/13/2026 07:30 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PPCB, PMCB, XBIO, and CELZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PPCB, PMCB, XBIO, and CELZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PPCB, PMCB, XBIO, and CELZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB, PMCB, XBIO, and CELZ Company Descriptions

Creative Medical Technology NASDAQ:CELZ

Nuvilex NASDAQ:PMCB

Propanc Biopharma NASDAQ:PPCB

Xenetic Biosciences NASDAQ:XBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PPCB, PMCB, XBIO, and CELZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PPCB, PMCB, XBIO, and CELZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PPCB, PMCB, XBIO, and CELZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB, PMCB, XBIO, and CELZ Company Descriptions

Creative Medical Technology NASDAQ:CELZ

Nuvilex NASDAQ:PMCB

Propanc Biopharma NASDAQ:PPCB

Xenetic Biosciences NASDAQ:XBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools